Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 27, 2026Food Research InternationalOpen Access

Postbiotic of Bifidobacterium breve i1088 alleviates type 2 diabetes by promoting GLP-1 secretion: identification of 5-hydroxyindoleacetic acid as a key active metabolite

View Full Paper
Ask AI
Bookmark
Share

Authors

XNXiaokang NiuYZYuanzhang ZhaoXWX Wang

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates B. breve i1088 effects on GLP-1 secretion in T2DM, suggesting new therapy implications.

Key Points

  • This study aims to assess the effect of Bifidobacterium breve i1088 lysate on GLP-1 secretion and identify its bioactive components.
  • In vitro assays on NCI-H716 enteroendocrine cells to evaluate GLP-1 secretion
  • Validation of lysate metabolic benefits in a T2DM mouse model
  • Untargeted metabolomics to profile bioactive substances of the lysate
  • In vitro, B. breve i1088 lysate significantly stimulated GLP-1 secretion in a dose-dependent manner.
  • High-dose lysate lowered glucose and lipids, showing anti-inflammatory effects, and outperformed live bacteria in stability.
  • 5-hydroxyindoleacetic acid was identified as the key metabolite driving GLP-1 release and upregulating GCG and PC1 expression.

Cite This Study

Niu et al. (2026) studied this question.

synapsesocial.com/papers/6a3f67aaaea7db3c1953f0eehttps://doi.org/10.1016/j.foodres.2026.119847
View Full Paper
Ask AI
Bookmark
Share